Skip to main content

Table 3 Effect of pramipexole versus ropinirole on cued recall according to patients’ pre-study dopamine agonist

From: Feasibility of a randomized single-blind crossover trial to assess the effects of the second-generation slow-release dopamine agonists pramipexole and ropinirole on cued recall memory in idiopathic mild or moderate Parkinson’s disease without cognitive impairment

Pre-study dopamine agonist

Drug

Condition

Estimate: mean (SD)

Difference (OFF–ON)

Mean (SD)

95% CI

PPX (n = 7)

PPX

OFF

0.366 (0.137)

0.034 (0.109)

−0.067, 0.135

 

ON

0.331 (0.140)

  

RPR

OFF

0.284 (0.152)

0.036 (0.194)

−0.144, 0.215

 

ON

0.249 (0.173)

  

RPR (n = 9)

PPX

OFF

0.417 (0.162)

0.027 (0.084)

−0.038, 0.091

 

ON

0.390 (0.168)

  

RPR

OFF

0.360 (0.155)

−0.016 (0.100)

−0.092, 0.061

 

ON

0.376 (0.147)

  
  1. PPX pramipexole PR, RPR ropinirole, SD standard deviation, CI confidence interval